NCT00266526View on ClinicalTrials.gov

Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 2003

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2005

Conditions
Birch Pollen Allergy
Interventions
BIOLOGICAL

Recombinant birch pollen

Trial Locations (1)

21465

Allergopharma GmbH & Co. KG, Reinbek

All Listed Sponsors
lead

Allergopharma GmbH & Co. KG

INDUSTRY

NCT00266526 - Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV | Biotech Hunter | Biotech Hunter